Diabetic Nephropathy & Hypertension

Diabetic nephrosis is characterised by cardiovascular disease, progressive proteinuria, glomerulosclerosis, and decline in capillary vessel filtration rate (GFR) resulting in ESRD. cardiovascular disease within the setting of polygenic disease is outlined as a pulse force per unit area force per unit area mmHg or a pulsation force per unit area force per unit area mmHg. associate elevated urinary simple protein excretion rate, exaggerated force per unit area (BP), and a continuous loss of excretory organ operate ar characteristics of DN. Screening for small proteinuria is central to polygenic disease care, and antihypertensive drug agents ar used for the first interference and treatment of DN. Angiotensin-converting accelerator inhibitors and angiotonin receptor blockers play central roles and have protecting properties on the far side their BP-lowering effects. BP management in relevancy DN is that the main focus of this review, however tight management of the aldohexose level is equally vital.

  • Hypertension Management
  • Pathogenesis of diabetic nephropathy
  • Hypertension-Clinical and Experimental Models
  • Diabetic Nephropathy–Biomarkers of Disease

Related Conference of Diabetic Nephropathy & Hypertension

February 21-22, 2022

Global Summit on Nephrology, Urology and Kidney Transplantation

Prague, Czech Republic
March 28-29, 2022

5th World Congress on Nephrology and Renal Care

Valencia, Spain
May 16-17, 2022

18th World Nephrology Conference

Tokyo, Japan
July 14-15, 2022

21st Annual Conference on Urology and Nephrological Disorders

Singapore City, Singapore
August 25-26, 2022

18th International Conference on Nephrology and Hypertension

Zurich, Switzerland
August 25-26, 2022

7th World Kidney Congress

Zurich, Switzerland
September 27-28, 2022

24th Global Nephrologists Annual Meeting

Berlin, Germany

Diabetic Nephropathy & Hypertension Conference Speakers

Recommended Sessions

Related Journals

Are you interested in